The proposed pluripotent IMPACTA PERU CTU is a consortium of researchers from the Asociacion Civil Impacta Salud y Educacion (IMPACTA), the Asociacion Civil Selva Amazonica (ACSA), the Hospital Nacional Dos de Mayo (HNDM), and the U.S. Naval Medical Research Center Detachment (NMRCD). The CTU headquarters are located at IMPACTA, a Non Governmental Organization devoted to HIV research, led by Dr. Jorge Sanchez and supported by a cadre of experienced researchers and promising junior investigators. It has been affiliated since year 2000 with the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN), and since 2002 with the AIDS Clinical Trials Group (ACTG). Financial support of over 15 million dollars has been invested by NIH in IMPACTA research sites during the last 5 years for optimal staff training and establishing a comprehensive clinical and laboratorial infrastructure for conducting multiple clinical research projects that meet Peruvian and U.S. regulatory standards. Our mission is to efficiently and ethically conduct the clinical research agenda proposed by HVTN, HPTN, and ACTG at four Clinical Research Sites (CRSs), three of them already network affiliated, namely Miraflores, Lince, and ACSA;and a new site that will strengthen the CTU capability to perform prevention and therapeutic research, namely the HNDM. Areas of particular interest are 1) Phase I to III clinical trials on HIV vaccine candidates or regimens, 2) evaluations of pre-exposure prophylaxis with antiretroviral treatment among uninfected men who have sex with men, 3) interventions to reduce HIV risky behaviors among HIV infected persons, 4) HIV prevention trials using treatment of HSV-2 co-infection to decrease HIV-1 genital shedding, 5) identify and intervene individuals with early/acute HIV infection to prevent HIV transmission or impact on the disease course, 6) evaluate the effectiveness of new antiretroviral regimens, 7) evaluate therapies and therapeutic strategies for treating co-infections and complications, and 8) optimize antiretroviral therapies on the basis of safety, adherence, resistance, and durability of response. Investigators from IMPACTA PERU CTU, who are already contributing to the research agenda of the networks as Scientific Committee members and as chairs of protocols in development, envision this pluripotent CTU to fully develop as a center for excellence in HIV Clinical Research in South America. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M2))
Program Officer
Csedrik, Joanne E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Asociacion Civil Impacta Salud Y Educacn
Zip Code
LIMA -04
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58
Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8
Lemos, M P; Karuna, S T; Mize, G J et al. (2016) In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. Mucosal Immunol 9:798-808
Lama, Javier R; Karuna, Shelly T; Grant, Shannon P et al. (2016) Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection. PLoS One 11:e0160487
Gross, Robert; Zheng, Lu; La Rosa, Alberto et al. (2015) Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. Lancet HIV 2:e12-9
Firnhaber, Cynthia; Smeaton, Laura M; Grinsztejn, Beatriz et al. (2015) Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials 16:89-99
Podany, Anthony T; Bao, Yajing; Swindells, Susan et al. (2015) Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis 61:1322-7

Showing the most recent 10 out of 19 publications